Sanofi-AstraZeneca RSV Prevention Antibody Appears Safe, Effective In Infants, FDA Reviewers Say
June 07, 2023
Reuters (6/6, Mahobe, Sunny) reports the FDA’s “staff reviewers said on Tuesday Sanofi and partner AstraZeneca’s experimental therapy to prevent respiratory syncytial virus (RSV) infections in infants appeared safe and effective.” The “RSV prevention anti...